Xiaolu Yu

910 total citations
29 papers, 643 citations indexed

About

Xiaolu Yu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaolu Yu has authored 29 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaolu Yu's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Immunotherapy and Immune Responses (4 papers). Xiaolu Yu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Immunotherapy and Immune Responses (4 papers). Xiaolu Yu collaborates with scholars based in China, United States and Switzerland. Xiaolu Yu's co-authors include Hailun Gu, Yakun Wan, Li Liu, Xingyao Li, Yongzhuo Huang, Binfan Chen, Likun Gong, Lifeng Ding, Bin Tu and Yingshu Wang and has published in prestigious journals such as Advanced Materials, Nature Materials and Journal of Clinical Oncology.

In The Last Decade

Xiaolu Yu

29 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaolu Yu China 15 266 192 159 126 92 29 643
Shan Cheng China 18 377 1.4× 109 0.6× 54 0.3× 93 0.7× 108 1.2× 67 734
Yan‐Jiun Huang Taiwan 17 354 1.3× 226 1.2× 80 0.5× 89 0.7× 135 1.5× 48 901
U‐Ging Lo United States 18 409 1.5× 168 0.9× 93 0.6× 192 1.5× 192 2.1× 24 770
Jinbo Yuan China 16 401 1.5× 189 1.0× 48 0.3× 37 0.3× 101 1.1× 35 667
Jianfeng Cui China 16 331 1.2× 173 0.9× 88 0.6× 149 1.2× 166 1.8× 46 736
Xipeng Wang China 12 267 1.0× 111 0.6× 157 1.0× 62 0.5× 206 2.2× 31 593
Shujuan Liang China 14 275 1.0× 71 0.4× 153 1.0× 29 0.2× 86 0.9× 27 565
G. Giuberti Italy 16 326 1.2× 185 1.0× 92 0.6× 58 0.5× 79 0.9× 23 726
Guohua Lu China 18 306 1.2× 172 0.9× 198 1.2× 125 1.0× 121 1.3× 38 697

Countries citing papers authored by Xiaolu Yu

Since Specialization
Citations

This map shows the geographic impact of Xiaolu Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaolu Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaolu Yu more than expected).

Fields of papers citing papers by Xiaolu Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaolu Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaolu Yu. The network helps show where Xiaolu Yu may publish in the future.

Co-authorship network of co-authors of Xiaolu Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaolu Yu. A scholar is included among the top collaborators of Xiaolu Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaolu Yu. Xiaolu Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Yi, Zijin Luo, Yan Zong, et al.. (2025). Tissue-specific mRNA delivery and prime editing with peptide–ionizable lipid nanoparticles. Nature Materials. 25(1). 133–145. 4 indexed citations
2.
Ren, Hongyu, Xiaolu Yu, Mengyao Li, et al.. (2025). Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases. Nano Letters. 25(37). 13802–13810. 1 indexed citations
3.
Liu, Wenjing, et al.. (2024). Pan-cancer analysis of NUDT21 and its effect on the proliferation of human head and neck squamous cell carcinoma. Aging. 16(4). 3363–3385. 2 indexed citations
4.
Li, Fanglin, Shiyi Chen, Xiaolu Yu, et al.. (2024). INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling. Acta Pharmacologica Sinica. 46(2). 448–461. 4 indexed citations
5.
Xu, Zheng, Su-Wan Hu, Yu Zhou, et al.. (2023). Corticotropin-releasing factor neurones in the paraventricular nucleus of the hypothalamus modulate isoflurane anaesthesia and its responses to acute stress in mice. British Journal of Anaesthesia. 130(4). 446–458. 6 indexed citations
6.
Yu, Xiaolu, et al.. (2022). Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner. Cancer Immunology Research. 11(2). 241–260. 6 indexed citations
7.
Yu, Xiaolu, et al.. (2022). Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. Frontiers in Immunology. 13. 910704–910704. 8 indexed citations
8.
Liu, Tianyu, Yue Wu, Liqiang Li, et al.. (2022). Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT. European Journal of Nuclear Medicine and Molecular Imaging. 49(6). 1810–1821. 17 indexed citations
9.
10.
Li, Fanglin, et al.. (2022). Different Immunoregulation Roles of Activin A Compared With TGF-β. Frontiers in Immunology. 13. 921366–921366. 14 indexed citations
11.
Deng, Qiangqiang, Qingli Zhang, Binfan Chen, et al.. (2020). Gigantol ameliorates CCl4-induced liver injury via preventing activation of JNK/cPLA2/12-LOX inflammatory pathway. Scientific Reports. 10(1). 22265–22265. 26 indexed citations
12.
Chen, Binfan, Ang Gao, Bin Tu, et al.. (2020). Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. Biomaterials. 255. 120187–120187. 105 indexed citations
13.
Yan, Xiaoxia, Hailong Li, Yiting Zhang, et al.. (2019). A new recombinant MS-superoxide dismutase alleviates 5-fluorouracil-induced intestinal mucositis in mice. Acta Pharmacologica Sinica. 41(3). 348–357. 30 indexed citations
14.
Yu, Xiaolu, et al.. (2018). Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR. Translational Cancer Research. 7(3). 600–608. 2 indexed citations
15.
Zhong, Wenjing, et al.. (2018). Sensitive detection of Bacillus thuringiensis Cry1B toxin based on camel single‐domain antibodies. MicrobiologyOpen. 7(4). e00581–e00581. 9 indexed citations
16.
Shen, Qing, et al.. (2018). Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR. Translational Cancer Research. 7(3). 600–608. 3 indexed citations
17.
Li, Xingyao, Xiaolu Yu, Xudan Liu, et al.. (2017). Oral Administration of Resveratrol Alleviates Osteoarthritis Pathology in C57BL/6J Mice Model Induced by a High-Fat Diet. Mediators of Inflammation. 2017. 1–11. 54 indexed citations
18.
Gu, Hailun, Xiaolu Yu, Xingyao Li, et al.. (2017). Resveratrol inhibits the IL-1β-induced expression of MMP-13 and IL-6 in human articular chondrocytes via TLR4/MyD88-dependent and -independent signaling cascades. International Journal of Molecular Medicine. 39(3). 734–740. 44 indexed citations
19.
Feng, Li‐Xing, Peng Sun, Miao Liu, et al.. (2016). Agglutinin isolated from Arisema heterophyllum Blume induces apoptosis and autophagy in A549 cells through inhibiting PI3K/Akt pathway and inducing ER stress. Chinese Journal of Natural Medicines. 14(11). 856–864. 24 indexed citations
20.
Yu, Xiaolu, et al.. (2010). e0126 Study on anti-oxidative function of four kinds of schizandrae lignans. Heart. 96(Suppl 3). A41.1–A41. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shan Cheng Breakdown of academic impact, for papers by Yan‐Jiun Huang Breakdown of academic impact, for papers by U‐Ging Lo Breakdown of academic impact, for papers by Jinbo Yuan Breakdown of academic impact, for papers by Jianfeng Cui Breakdown of academic impact, for papers by Xipeng Wang Breakdown of academic impact, for papers by Shujuan Liang Breakdown of academic impact, for papers by G. Giuberti Breakdown of academic impact, for papers by Guohua Lu
Rankless by CCL
2026